Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and Emergence of Resistant Mutants in an In Vitro Pharmacokinetic-Pharmacodynamic Model

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 946-953

  Ba, Boubakar B ^a   Feghali, Hala ^a   Arpin, Corinne ^a   Saux, Marie Claude ^a   Quentin, Claudine ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TETRACYCLINE; TIMENTIN; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL REGROWTH; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GROWTH CURVE; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIPLE DRUG DOSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PHARMACODYNAMIC MODEL; PHARMACOKINETICS; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; CIPROFLOXACIN; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE, BACTERIAL; HALF-LIFE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTATION; QUINOLINES; STENOTROPHOMONAS MALTOPHILIA;

EID: 1442275661     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.946-953.2004     Document Type: Article

References (40)

1. Alonso, A., and J. L. Martinez. 1997. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41:1140-1142.
2. Alonso, A., and J. L. Martinez. 2000. Cloning and characterization of Sme-DEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 44:3079-3086.
3. Alonso, A., and J. L. Martinez. 2001. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 45:1879-1881.
4. Ba, B. B., A. Bernard, A. Iliadis, C. Quentin, D. Ducint, R. Etienne, M. Fourtillan, I. Maachi-Guillot, and M.-C. Saux. 2001. New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin. J. Antimicrob. Chemother. 47:223-227.
5. Ba, B. B., D. Ducint, M. Fourtillan, and M.-C. Saux. 1998. Fully automated high-performance liquid chromatography of ciprofloxacin with direct injection of plasma and Mueller-Hinton broth for pharmacokinetic/ pharmacodynamic studies. J. Chromatogr. B 714:317-324.
6. Ba, B. B., R. Etienne, D. Ducint, C. Quentin, and M.-C. Saux. 2001. Determination of moxifloxacin in growth media by high-performance liquid chromatography. J. Chromatogr. B 754:107-112.
7. Balfour, J. A., and H. M. Lamb. 2000. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 59:115-139.
8. Bergogne-Bérézin, E. 2002. Clinical role of protein binding of quinolones. Clin. Pharmacokinet. 41:741-750.
9. Bowker, K. E., M. Wootton, C. A. Rogers, R. Lewis, H. A. Holt, and A. P. MacGowan. 1999. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. J. Antimicrob. Chemother. 44:661-667.
10. Crump, B., R. Wise, and J. Dent. 1983. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob. Agents Chemother. 24:784-786.
11. Dalhoff, A. 1999. Pharmacodynamics of fluoroquinolones. J. Antimicrob. Chemother. 43(Suppl. B):51-59.
12. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
13. Denton, M., and K. G. Kerr. 1998. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microb. Rev. 11:57-80.
14. Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
15. Firsov, A. A., A. A. Shevchenko, S. N. Vostrov, and S. H. Zinner. 1998. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:659-665.
16. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
17. Fourtillan, J. B. 1990. Caractéristiques pharmacociné tiques de la ciprofloxacine par voies orale et intraveineuse. Med. Mal. Infect. 20:33-37.
18. Gales, A. C., R. N. Jones, K. R. Forward, J. Liñares, H. S. Sader, and J. Verhoef. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin. Infect. Dis. 32(Suppl. 2):104-113.
19. Garrison, M. W., D. E. Anderson, D. M. Campbell, K. C. Carroll, C. L. Malone, J. D. Anderson, R. J. Hollis, and M. A. Pfaller. 1996. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob. Agents Chemother. 40:2859-2864.
20. Hancock, R. E. W. 1998. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin. Infect. Dis. 27(Suppl. 1):93-99.
21. Klepser, M. E., E. J. Ernst, C. R. Petzold, P. Rhomberg, and G. V. Doern. 2001. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob. Agents Chemother. 45:673-678.
22. Lecso-Bornet, M., J. Pierre, D. Sarkis-Karam, S. Lubera, and E. Bergogne-Berezin. 1992. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob. Agents Chemother. 36:669-671.
23. Lister, P. D. 2001. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin. Infect. Dis. 32(Suppl. 1):33-38.
24. MacGowan, A. P., K. E. Bowker, M. Wootton, and H. A. Holt. 1999. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield group A and G. J. Antimicrob. Chemother. 44:761-766.
25. MacGowan, A., C. Rogers, H. A. Holt, M. Wootton, and K. Bowker. 2000. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. J. Antimicrob. Chemother. 46:73-78.
26. Madaras-Kelly, K. J., B. E. Ostergaard, L. B. Hovde, and J. C. Rotschafer. 1996. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632.
27. Marchbanks, C. R., J. R. McKiel, D. H. Gilbert, N. J. Robillard, B. Painter, S. H. Zinner, and M. N. Dudley. 1993. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob. Agents Chemother. 37:1756-1763.
28. Muñoz Bellido, J. L., F. J. Sánchez-Hernández, M. N. Gutiérrez Zufiaurre, and J. A. García-Rodríguez. 2000. In vitro activity of newer fluoroquinolones against Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 46:323-342.
29. Nightingale, C. H. 2000. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 20:245-256.
30. Poole, K. 2001. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J. Mol. Microbiol. Biotechnol. 3:255-264.
31. Poulos, C. D., S. O. Matsumura, B. M. Willey, D. E. Low, and A. McGeer. 1995. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob. Agents Chemother. 39:2220-2223.
32. Robin, T., and J. M. Janda. 1996. Pseudo-, Xantho-, Stenotrophomonas maltophilia: an emerging pathogen in search of a genus. Clin. Microbiol. Newsl. 18:9-13.
33. Stass, H., and D. Kubitza. 1999. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J. Antimicrob. Chemother. 43(Suppl. B):83-90.
34. Stein, G. E. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23(Suppl. 1):19-24.
35. Valdezate, S., A. Vindel, A. Echeita, F. Baquero, and R. Cantón. 2002. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrob. Agents Chemother. 46:665-671.
36. Vartivarian, S., E. Anaissie, G. Bodey, H. Sprigg, and K. Rolston. 1994. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob. Agents Chemother. 38:624-627.
37. Weiss, K., C. Restieri, E. De Carolis, M. Laverdière, and H. Guay. 2000. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 45:363-365.
38. Wüst, J., R. Frei, H. Günthard, and M. Altwegg. 1995. Analysis of restriction fragment length polymorphism and ribotyping of multiresistant Stenotrophomonas maltophilia isolated from persisting lung infection in a cystic fibrosis patient. Scand. J. Infect. Dis. 27:499-502.
39. Zhang, L., X.-Z. Li, and K. Poole. 2000. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob. Agents Chemother. 44:287-293.
40. Zhang, L., X.-Z. Li, and K. Poole. 2001. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. J. Antimicrob. Chemother. 48:549-552.